Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KFRX03
Therapeutic Area : Neurology
Study Phase : IND Enabling
Recipient : Georgetown University
Deal Size : Undisclosed
Deal Type : Licensing Agreement
KeifeRx Expands Licensing Agreement with Georgetown University for Kinase Inhibitors
Details : Under the agreement, KeifeRx will develop novel TKI chemical entities for treating neurodegenerative, neuroinflammatory, and mast cell-associated diseases, including KFRX03 and KFRX04.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 01, 2024
Lead Product(s) : KFRX03
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Recipient : Georgetown University
Deal Size : Undisclosed
Deal Type : Licensing Agreement
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
Details : Proceeds from the financing will advance pipeline of optimized, low dose, orally delivered tyrosine kinase inhibitors including Nilotinib BE for the treatment of multiple neurodegenerative diseases.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 12, 2021